Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Molecular expression patterns in the synovium and their association with advanced symptomatic knee osteoarthritis.

Wyatt LA, Nwosu LN, Wilson D, Hill R, Spendlove I, Bennett AJ, Scammell BE, Walsh DA.

Osteoarthritis Cartilage. 2019 Apr;27(4):667-675. doi: 10.1016/j.joca.2018.12.012. Epub 2018 Dec 28.

PMID:
30597276
2.

Connexin 43 is an independent predictor of patient outcome in breast cancer patients.

Chasampalioti M, Green AR, Ellis IO, Rakha EA, Jackson AM, Spendlove I, Ramage JM.

Breast Cancer Res Treat. 2019 Feb;174(1):93-102. doi: 10.1007/s10549-018-5063-9. Epub 2018 Nov 24.

3.

A HIF-LIMD1 negative feedback mechanism mitigates the pro-tumorigenic effects of hypoxia.

Foxler DE, Bridge KS, Foster JG, Grevitt P, Curry S, Shah KM, Davidson KM, Nagano A, Gadaleta E, Rhys HI, Kennedy PT, Hermida MA, Chang TY, Shaw PE, Reynolds LE, McKay TR, Wang HW, Ribeiro PS, Plevin MJ, Lagos D, Lemoine NR, Rajan P, Graham TA, Chelala C, Hodivala-Dilke KM, Spendlove I, Sharp TV.

EMBO Mol Med. 2018 Aug;10(8). pii: e8304. doi: 10.15252/emmm.201708304.

4.

High mobility group protein B1 is a predictor of poor survival in ovarian cancer.

Machado LR, Moseley PM, Moss R, Deen S, Nolan C, Spendlove I, Ramage JM, Chan SY, Durrant LG.

Oncotarget. 2017 Aug 24;8(60):101215-101223. doi: 10.18632/oncotarget.20538. eCollection 2017 Nov 24.

5.

A prebiotic galactooligosaccharide mixture reduces severity of hyperpnoea-induced bronchoconstriction and markers of airway inflammation.

Williams NC, Johnson MA, Shaw DE, Spendlove I, Vulevic J, Sharpe GR, Hunter KA.

Br J Nutr. 2016 Sep;116(5):798-804. doi: 10.1017/S0007114516002762.

PMID:
27523186
6.

Stromal fibroblasts support dendritic cells to maintain IL-23/Th17 responses after exposure to ionizing radiation.

Malecka A, Wang Q, Shah S, Sutavani RV, Spendlove I, Ramage JM, Greensmith J, Franks HA, Gough MJ, Saalbach A, Patel PM, Jackson AM.

J Leukoc Biol. 2016 Aug;100(2):381-9. doi: 10.1189/jlb.3A1015-474R. Epub 2016 Apr 5.

7.

Monoclonal Antibodies Targeting LecLex-Related Glycans with Potent Antitumor Activity.

Chua JX, Vankemmelbeke M, McIntosh RS, Clarke PA, Moss R, Parsons T, Spendlove I, Zaitoun AM, Madhusudan S, Durrant LG.

Clin Cancer Res. 2015 Jul 1;21(13):2963-74. doi: 10.1158/1078-0432.CCR-14-3030. Epub 2015 Mar 16.

8.

Structural biology of antibody recognition of carbohydrate epitopes and potential uses for targeted cancer immunotherapies.

Dingjan T, Spendlove I, Durrant LG, Scott AM, Yuriev E, Ramsland PA.

Mol Immunol. 2015 Oct;67(2 Pt A):75-88. doi: 10.1016/j.molimm.2015.02.028. Epub 2015 Mar 7. Review.

PMID:
25757815
9.

CD55 costimulation induces differentiation of a discrete T regulatory type 1 cell population with a stable phenotype.

Sutavani RV, Bradley RG, Ramage JM, Jackson AM, Durrant LG, Spendlove I.

J Immunol. 2013 Dec 15;191(12):5895-903. doi: 10.4049/jimmunol.1301458. Epub 2013 Nov 6.

10.

The ataxia telangiectasia mutated kinase pathway regulates IL-23 expression by human dendritic cells.

Wang Q, Franks HA, Lax SJ, El Refaee M, Malecka A, Shah S, Spendlove I, Gough MJ, Seedhouse C, Madhusudan S, Patel PM, Jackson AM.

J Immunol. 2013 Apr 1;190(7):3246-55. doi: 10.4049/jimmunol.1201484. Epub 2013 Mar 4.

11.

Therapeutic targeting of Lewis(y) and Lewis(b) with a novel monoclonal antibody 692/29.

Noble P, Spendlove I, Harding S, Parsons T, Durrant LG.

PLoS One. 2013;8(2):e54892. doi: 10.1371/journal.pone.0054892. Epub 2013 Feb 8.

12.

Elevation of alanine transaminase and markers of liver fibrosis after a mixed meal challenge in individuals with type 2 diabetes.

Khoo EY, Stevenson MC, Leverton E, Cross R, Eriksson JW, Poucher SM, Spendlove I, Morris PG, Macdonald IA, Mansell P, Aithal GP.

Dig Dis Sci. 2012 Nov;57(11):3017-25. doi: 10.1007/s10620-012-2219-z. Epub 2012 May 17.

PMID:
22592631
13.

The chemokine, CXCL12, is an independent predictor of poor survival in ovarian cancer.

Popple A, Durrant LG, Spendlove I, Rolland P, Scott IV, Deen S, Ramage JM.

Br J Cancer. 2012 Mar 27;106(7):1306-13. doi: 10.1038/bjc.2012.49. Epub 2012 Mar 13.

14.

Immunology in the clinic review series; focus on cancer: glycolipids as targets for tumour immunotherapy.

Durrant LG, Noble P, Spendlove I.

Clin Exp Immunol. 2012 Feb;167(2):206-15. doi: 10.1111/j.1365-2249.2011.04516.x. Review.

15.

Using monoclonal antibodies to stimulate antitumor cellular immunity.

Durrant LG, Pudney VA, Spendlove I.

Expert Rev Vaccines. 2011 Jul;10(7):1093-106. doi: 10.1586/erv.11.33. Review.

PMID:
21806402
16.

Single shot tetanus vaccine manufactured by a supercritical fluid encapsulation technology.

Baxendale A, van Hooff P, Durrant LG, Spendlove I, Howdle SM, Woods HM, Whitaker MJ, Davies OR, Naylor A, Lewis AL, Illum L.

Int J Pharm. 2011 Jul 15;413(1-2):147-54. doi: 10.1016/j.ijpharm.2011.04.053. Epub 2011 Apr 28.

PMID:
21554938
17.

Vaccines as early therapeutic interventions for cancer therapy: neutralising the immunosuppressive tumour environment and increasing T cell avidity may lead to improved responses.

Durrant LG, Pudney V, Spendlove I, Metheringham RL.

Expert Opin Biol Ther. 2010 May;10(5):735-48. doi: 10.1517/14712591003769790. Review.

PMID:
20384522
18.

Antibodies designed as effective cancer vaccines.

Metheringham RL, Pudney VA, Gunn B, Towey M, Spendlove I, Durrant LG.

MAbs. 2009 Jan-Feb;1(1):71-85.

19.

The role of CD97 in regulating adaptive T-cell responses.

Spendlove I, Sutavani R.

Adv Exp Med Biol. 2010;706:138-48. Review.

PMID:
21618833
20.

DNA vaccination with T-cell epitopes encoded within Ab molecules induces high-avidity anti-tumor CD8+ T cells.

Pudney VA, Metheringham RL, Gunn B, Spendlove I, Ramage JM, Durrant LG.

Eur J Immunol. 2010 Mar;40(3):899-910. doi: 10.1002/eji.200939857.

21.

Cytoplasmic p27 expression is an independent prognostic factor in ovarian cancer.

Duncan TJ, Al-Attar A, Rolland P, Harper S, Spendlove I, Durrant LG.

Int J Gynecol Pathol. 2010 Jan;29(1):8-18. doi: 10.1097/PGP.0b013e3181b64ec3.

PMID:
19952944
22.

The chromosome 3p21.3-encoded gene, LIMD1, is a critical tumor suppressor involved in human lung cancer development.

Sharp TV, Al-Attar A, Foxler DE, Ding L, de A Vallim TQ, Zhang Y, Nijmeh HS, Webb TM, Nicholson AG, Zhang Q, Kraja A, Spendlove I, Osborne J, Mardis E, Longmore GD.

Proc Natl Acad Sci U S A. 2008 Dec 16;105(50):19932-7. doi: 10.1073/pnas.0805003105. Epub 2008 Dec 5.

23.

Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis.

Aithal GP, Thomas JA, Kaye PV, Lawson A, Ryder SD, Spendlove I, Austin AS, Freeman JG, Morgan L, Webber J.

Gastroenterology. 2008 Oct;135(4):1176-84. doi: 10.1053/j.gastro.2008.06.047. Epub 2008 Jun 25.

PMID:
18718471
24.

Differential subcellular localisation of the tumour suppressor protein LIMD1 in breast cancer correlates with patient survival.

Spendlove I, Al-Attar A, Watherstone O, Webb TM, Ellis IO, Longmore GD, Sharp TV.

Int J Cancer. 2008 Nov 15;123(10):2247-53. doi: 10.1002/ijc.23851.

25.

T-cell responses in osteosarcoma patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55.

Ullenhag GJ, Spendlove I, Watson NF, Kallmeyer C, Pritchard-Jones K, Durrant LG.

Clin Immunol. 2008 Aug;128(2):148-54. doi: 10.1016/j.clim.2008.03.512. Epub 2008 May 27.

PMID:
18508409
26.

Vascular endothelial growth factor expression in ovarian cancer: a model for targeted use of novel therapies?

Duncan TJ, Al-Attar A, Rolland P, Scott IV, Deen S, Liu DT, Spendlove I, Durrant LG.

Clin Cancer Res. 2008 May 15;14(10):3030-5. doi: 10.1158/1078-0432.CCR-07-1888.

27.

Upregulation of MICA on high-grade invasive operable breast carcinoma.

Madjd Z, Spendlove I, Moss R, Bevin S, Pinder SE, Watson NF, Ellis I, Durrant LG.

Cancer Immun. 2007 Oct 22;7:17.

28.

Loss of IFN gamma receptor is an independent prognostic factor in ovarian cancer.

Duncan TJ, Rolland P, Deen S, Scott IV, Liu DT, Spendlove I, Durrant LG.

Clin Cancer Res. 2007 Jul 15;13(14):4139-45.

29.

Human leukocyte antigen class I antigen expression is an independent prognostic factor in ovarian cancer.

Rolland P, Deen S, Scott I, Durrant L, Spendlove I.

Clin Cancer Res. 2007 Jun 15;13(12):3591-6.

30.

Structural and functional characterization of a novel T cell receptor co-regulatory protein complex, CD97-CD55.

Abbott RJ, Spendlove I, Roversi P, Fitzgibbon H, Knott V, Teriete P, McDonnell JM, Handford PA, Lea SM.

J Biol Chem. 2007 Jul 27;282(30):22023-32. Epub 2007 Apr 20.

31.

The ubiquitin-binding protein p62 is expressed in breast cancers showing features of aggressive disease.

Rolland P, Madjd Z, Durrant L, Ellis IO, Layfield R, Spendlove I.

Endocr Relat Cancer. 2007 Mar;14(1):73-80.

PMID:
17395976
32.

The p53 positive Bcl-2 negative phenotype is an independent marker of prognosis in breast cancer.

Rolland P, Spendlove I, Madjd Z, Rakha EA, Patel P, Ellis IO, Durrant L.

Int J Cancer. 2007 Mar 15;120(6):1311-7. Erratum in: Int J Cancer. 2007 Aug 15;121(4):928. Madjid, Zahra [corrected to Madjd, Zahra].

33.

A neoadjuvant/adjuvant randomized trial of colorectal cancer patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55.

Ullenhag GJ, Spendlove I, Watson NF, Indar AA, Dube M, Robins RA, Maxwell-Armstrong C, Scholefield JH, Durrant LG.

Clin Cancer Res. 2006 Dec 15;12(24):7389-96. Epub 2006 Nov 22.

34.

Cytoplasmic expression of p27(kip1) is associated with a favourable prognosis in colorectal cancer patients.

Watson NF, Durrant LG, Scholefield JH, Madjd Z, Scrimgeour D, Spendlove I, Ellis IO, Patel PM.

World J Gastroenterol. 2006 Oct 21;12(39):6299-304.

35.

Costimulation via CD55 on human CD4+ T cells mediated by CD97.

Capasso M, Durrant LG, Stacey M, Gordon S, Ramage J, Spendlove I.

J Immunol. 2006 Jul 15;177(2):1070-7.

36.

Complement decay accelerating factor (DAF)/CD55 in cancer.

Spendlove I, Ramage JM, Bradley R, Harris C, Durrant LG.

Cancer Immunol Immunother. 2006 Aug;55(8):987-95. Epub 2006 Feb 17.

PMID:
16485129
37.

The use of reverse immunology to identify HLA-A2 binding epitopes in Tie-2.

Ramage JM, Spendlove I, Rees R, Moss RS, Durrant LG.

Cancer Immunol Immunother. 2006 Aug;55(8):1004-10. Epub 2006 Jan 12.

PMID:
16408213
38.

Expression of the stress-related MHC class I chain-related protein MICA is an indicator of good prognosis in colorectal cancer patients.

Watson NF, Spendlove I, Madjd Z, McGilvray R, Green AR, Ellis IO, Scholefield JH, Durrant LG.

Int J Cancer. 2006 Mar 15;118(6):1445-52.

39.

High expression of Lewis y/b antigens is associated with decreased survival in lymph node negative breast carcinomas.

Madjd Z, Parsons T, Watson NF, Spendlove I, Ellis I, Durrant LG.

Breast Cancer Res. 2005;7(5):R780-7. Epub 2005 Jul 28.

40.

Expression of the membrane complement regulatory protein CD59 (protectin) is associated with reduced survival in colorectal cancer patients.

Watson NF, Durrant LG, Madjd Z, Ellis IO, Scholefield JH, Spendlove I.

Cancer Immunol Immunother. 2006 Aug;55(8):973-80. Epub 2005 Sep 3.

PMID:
16151805
41.

Evidence that the p53 negative / Bcl-2 positive phenotype is an independent indicator of good prognosis in colorectal cancer: a tissue microarray study of 460 patients.

Watson NF, Madjd Z, Scrimegour D, Spendlove I, Ellis IO, Scholefield JH, Durrant LG.

World J Surg Oncol. 2005 Jul 19;3:47.

42.

Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis.

Watson NF, Ramage JM, Madjd Z, Spendlove I, Ellis IO, Scholefield JH, Durrant LG.

Int J Cancer. 2006 Jan 1;118(1):6-10.

43.

Total loss of MHC class I is an independent indicator of good prognosis in breast cancer.

Madjd Z, Spendlove I, Pinder SE, Ellis IO, Durrant LG.

Int J Cancer. 2005 Nov 1;117(2):248-55.

44.

Immune responses to the 105AD7 human anti-idiotypic vaccine after intensive chemotherapy, for osteosarcoma.

Pritchard-Jones K, Spendlove I, Wilton C, Whelan J, Weeden S, Lewis I, Hale J, Douglas C, Pagonis C, Campbell B, Alvarez P, Halbert G, Durrant LG.

Br J Cancer. 2005 Apr 25;92(8):1358-65.

45.

Do poor-prognosis breast tumours express membrane cofactor proteins (CD46)?

Madjd Z, Durrant LG, Pinder SE, Ellis IO, Ronan J, Lewis S, Rushmere NK, Spendlove I.

Cancer Immunol Immunother. 2005 Feb;54(2):149-56. Epub 2004 Sep 16.

PMID:
15378282
46.

A novel CEA vaccine stimulates T cell proliferation, gammaIFN secretion and CEA specific CTL responses.

Parsons T, Spendlove I, Nirula R, Writer M, Carter G, Carr F, Durrant LG.

Vaccine. 2004 Sep 3;22(25-26):3487-94.

PMID:
15308376
47.

Loss of CD55 is associated with aggressive breast tumors.

Madjd Z, Durrant LG, Bradley R, Spendlove I, Ellis IO, Pinder SE.

Clin Cancer Res. 2004 Apr 15;10(8):2797-803.

48.

Identification of an HLA-A*0201 cytotoxic T lymphocyte epitope specific to the endothelial antigen Tie-2.

Ramage JM, Metheringham R, Conn A, Spendlove I, Moss RS, Patton DT, Murray JC, Rees RC, Durrant LG.

Int J Cancer. 2004 Jun 10;110(2):245-50.

49.

Comparison of the immune response to a self antigen after DNA immunisation of HLA*A201/H-2Kb and HHD transgenic mice.

Ramage JM, Metheringham R, Moss R, Spendlove I, Rees R, Durrant LG.

Vaccine. 2004 Apr 16;22(13-14):1728-31.

PMID:
15068856
50.

Cancer vaccines entering Phase III clinical trials.

Durrant LG, Spendlove I.

Expert Opin Emerg Drugs. 2003 Nov;8(2):489-500. Review.

PMID:
14662001

Supplemental Content

Loading ...
Support Center